1 Result: Ipsen
Momentum Surge: Elafibranor's PBC Trial Data Boosts Genfit
June 30th, 2023
Ipsen S.A. (OTCMKTS: IPSEY) and Genfit S.A. (Nasdaq: GNFT) have announced positive results from the ELATIVE Phase III trial evaluating elafibranor as a treatment for patients with primary biliary cholangitis (PBC), a rare cholestatic liver disease, w. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Countdown to Earnings: Xylem, Datadog, and Fiserv in Spotlight
February 08th, 2026Biotech Earnings Ahead for Exelixis, Gilead Sciences, Incyte
February 08th, 2026Arch Capital, Dynatrace, Cleveland-Cliffs Headline Earnings Calendar
February 08th, 2026NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026
Member Login